Silexion Therapeutics Corp (SLXN) - Dilution Analysis

8-K filing: Stock split 1-for-10 | Outstanding: 4,189,954 → 418,995

10-Q filing | 4.2M shares outstanding

POS AM filing: This prospectus relates to the issuance of up to 2,710,945 ordinary shares of Silexion Therapeutics Corp issuable upon the exercise of warrants that were issued as part of public offerings in September 2025 and January 2025.

POS AM filing: This prospectus relates to the issuance of up to 2,710,945 ordinary shares of Silexion Therapeutics Corp issuable upon the exercise of warrants that were issued as part of public offerings in September 2025 and January 2025.

S-3 filing: S-3 filing registers the resale of up to 1,292,348 ordinary shares and up to 372 warrants by selling securityholders.

8-K filing: Silexion Therapeutics Corp issued 450,000 ordinary shares to Moringa Sponsor, LP upon conversion of $1.8 million of the outstanding amount under the Amended and Restated Promissory Note at a conversion price of $4.00 per ordinary share. ($17.38M proceeds)

8-K filing: Silexion Therapeutics Corp completed a public offering of ordinary shares, pre-funded warrants, Series A ordinary warrants, and Series B ordinary warrants on September 12, 2025, raising approximately $6.0 million in gross proceeds. ($6.0M proceeds)

S-1 filing: S-1 filing for Silexion Therapeutics Corp proposing a combination offering of ordinary shares, pre-funded warrants, Series A ordinary warrants, and Series B ordinary warrants, with the intention of using the net proceeds for pre-clinical and clinical studies and general corporate purposes.

S-1 filing: This is an S-1 filing for a shelf registration of ordinary shares offered by Selling Securityholders and registration of warrants issued in prior transactions.

10-Q filing | 0.7M shares outstanding

8-K filing: Silexion Therapeutics Corp entered into an inducement offer letter agreement with certain holders to exercise Existing Warrants for cash at a reduced price of $11.57 per share, issuing New Warrants to purchase up to 304,212 ordinary shares at $11.32 per share, with expected gross proceeds of approximately $1.8 million. ($1.76M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 579,492 → 38,632

8-K filing: Stock split 1-for-15 | Outstanding: 8,692,392 → 579,492

POS AM filing: This POS AM filing includes information on other expenses of issuance and distribution, indemnification of directors and officers, and recent sales of unregistered securities including the issuance of the EarlyBird Convertible Note and the White Lion Purchase Agreement.

10-Q filing | 8.7M shares outstanding

POS AM filing: This POS AM filing relates to the registration of ordinary shares and warrants previously issued in connection with the closing of a business combination, offered by selling securityholders.

POS AM filing: This POS AM filing relates to the registration of ordinary shares issuable upon the exercise of warrants, including both ordinary warrants and placement agent warrants from a previous offering.

POS AM filing: This is a POS AM filing for New Silexion registering the resale of ordinary shares and ordinary warrants by selling securityholders.

POS AM filing: This POS AM filing relates to the registration of ordinary shares issuable upon the exercise of warrants from a previous offering, specifically the January 2025 Public Offering.

S-1/A filing: This S-1/A filing relates to the resale of up to 2,377,030 ordinary shares by selling securityholders, issuable upon the exercise of warrants, and also includes information regarding a January 2025 warrant inducement transaction.

10-K filing | 8414.6M shares outstanding

8-K filing: Silexion Therapeutics Corp entered into a Note Conversion Inducement Agreement with EarlyBirdCapital, Inc. to retire a convertible promissory note, involving a cash payment, the issuance of 277,777 ordinary shares to EBC, and a remaining balance payment.

S-1 filing: S-1 filing on 2025-02-12 for the resale of up to 2,377,030 ordinary shares by selling securityholders.

8-K filing: Silexion Therapeutics Corp entered into an inducement offer letter agreement with certain holders of existing warrants to purchase ordinary shares, with the holders agreeing to exercise their existing warrants for cash in consideration of the Company's agreement to issue new ordinary share purchase warrants. ($3.3M proceeds)

8-K filing: Silexion Therapeutics Corp completed a public offering of ordinary shares, pre-funded warrants, and investor warrants for gross proceeds of approximately $5 million, with H.C. Wainwright & Co., LLC acting as the sole placement agent. ($5.0M proceeds)

S-1/A filing: Silexion Therapeutics Corp is offering up to 2,577,320 ordinary shares, up to 2,577,320 pre-funded warrants, and placement agent warrants to purchase ordinary shares in a best-efforts offering.

S-1/A filing: S-1/A filing for offering up to 2,577,320 ordinary shares and accompanying warrants, and up to 2,577,320 pre-funded warrants and accompanying warrants at an assumed price of $1.94 per share.

8-K filing: Stock split 1-for-9 | Outstanding: 14,427,814,000 → 1,603,090,442

10-Q filing | 14427.8M shares outstanding

S-1 filing: S-1 filing for ordinary shares, pre-funded warrants, and placement agent warrants, along with ordinary shares issuable upon exercise of warrants.

S-1 filing: This S-1 filing is for a preliminary prospectus to register the issuance of ordinary shares upon exercise of warrants and resale of ordinary shares and warrants by selling securityholders.

S-1 filing: This prospectus relates to the potential offer and sale of 15,337,500 ordinary shares of Silexion Therapeutics Corp by White Lion Capital, LLC.

10-Q filing | 9.8M shares outstanding

8-K filing: Moringa completed a business combination with Silexion, including PIPE financing, an ELOC facility, and other related agreements. ($2.0M proceeds)